Esterase responsive release of anti-cancer agents from conjugated lipid nanocarrier and the regulatory considerations

Author:

Varpe Priya1ORCID,Joga Ramesh1ORCID,Aglave Gayatri1ORCID,Vasu Pavan1ORCID,Yerram Sravani1ORCID,Bellapu Kiran Kumar1ORCID,Srivastava Saurabh2ORCID,Kumar Sandeep13ORCID

Affiliation:

1. Department of Regulatory Affairs, National Institute of Pharmaceutical Education & Research-Hyderabad, Balanagar, Hyderabad, Telangana, 500037, India

2. Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research-Hyderabad, Balanagar, Hyderabad, Telangana , 500037, India

3. Department of Pharmaceutics, Nims Institute of Pharmacy, Nims University Rajasthan, Jaipur, Rajasthan,  303121, India

Publisher

Informa UK Limited

Reference42 articles.

1. Breast Cancer Statistics. https://www.cancer.net/cancer-types/breast-cancer/statistics#:∼:text=Currently%2C%20there%20are%20more%20than the%20United%20States%20in%202023

2. Global Cancer Statistics 2022: the trends projection analysis;Chhikara BS;Chem Biol Lett.,2023

3. Neoadjuvant immunotherapy of locoregionally advanced solid tumors

4. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer

5. Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3